Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Reproductive Health Medication Abortion topic
No spam. Unsubscribe anytime.
Senate hears AB 260 to protect access to medication abortion and telehealth services in California
Summary
AB 260 would protect access to mifepristone and expand telehealth delivery and labeling protections for medication abortion in California. Supporters said federal threats to approvals make state protections urgent; testimony included clinicians and reproductive‑rights groups. The measure advanced from committee.
Majority Leader (presenting AB 260) and bill supporters told the Senate Health Committee that the measure is designed to protect access to medication abortion — specifically mifepristone — and telehealth delivery in the face of recent federal threats and regulatory uncertainty.
The majority leader described AB 260 as “an important proposal to protect safe and legal reproductive health care here in California,” saying the bill would shield clinicians, pharmacists and clinics from disciplinary or licensure penalties for lawfully providing mifepristone and would require health plans to continue covering medication abortion. The bill would also allow removal of clinician names from prescription labels, following a model adopted in other states, and expand telehealth access for medication abortion.
Witnesses in support included Dr. Kelly Pfeiffer, who described providing medication‑abortion care in California and by telehealth to people traveling from states with bans; she told the committee, “AB 260 will help by protecting access to the medications we use for abortion.” Miranda Pond of Reproductive Freedom For All California, a cosponsor, said the bill would codify evidence‑based standards and protect providers and patients should federal actions restrict mifepristone.
Supporters argued that telehealth and medication abortion are safe and important access tools for patients who live far from providers or who cannot travel. They urged swift action in light of recent federal developments including a reported review of FDA approvals.
Committee action: The committee considered amendments and moved AB 260 to a subsequent committee (the hearing record shows referral to Business, Professions and Economic Development). Committee roll calls and quorum procedures placed the item on call; the hearing transcript recorded vote counts during the session (noting on‑call tallies and later recorded committee counts). The committee advanced the bill for further consideration.
Context: Supporters framed AB 260 as a preemptive, protective measure responsive to federal actions; opponents (not prominent in the hearing) were not the primary witnesses in the Senate Health hearing. The bill drew a broad coalition of advocacy and health organizations in support.
